Boehringer Challenges Medicare Drug Price Negotiation Law

By Aaron Keller · August 21, 2023, 4:27 PM EDT

Boehringer Ingelheim Pharmaceuticals Inc. has filed another in a string of constitutional challenges to the Inflation Reduction Act, arguing that the U.S. Department of Health and Human Services is derailing drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

Case Number

3:23-cv-01103

Court

Connecticut

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 18, 2023

Recent Articles By Aaron

December 03, 2024
$1B Sandoz Placeholder Bid Needs More Support, Judge Says
November 04, 2024
Cigna Scores $7.3M Verdict Against Fla. Drug Testing Labs
October 30, 2024
Cigna Wants $16.1M, Florida Labs Seek $5.1M In Benefits Feud
October 10, 2024
Yale Hospital Says Pension Liens Breach $435M Sale Deal
September 09, 2024
Yale Clinic Signs 'Substantial' Deal In Missing Fentanyl Claims
September 05, 2024
Conn. Dentist Admits To Reaping $2.2M Through Kickbacks
August 30, 2024
Connecticut Judge Wants More Info In Doctors' Billing Row
August 29, 2024
Conn. ER Docs Ask To Drop Harvard Pilgrim Insurance Fight
August 21, 2024
Conn. Justices Back Insurer's Out-Of-Network Patient Bills
August 20, 2024
Yale Health Liable For 840,000-Patient Data Breach, Suit Says